MX2021013663A - Composiciones y métodos para el tratamiento de las condiciones pulmonares relacionadas con biopeliculas. - Google Patents
Composiciones y métodos para el tratamiento de las condiciones pulmonares relacionadas con biopeliculas.Info
- Publication number
- MX2021013663A MX2021013663A MX2021013663A MX2021013663A MX2021013663A MX 2021013663 A MX2021013663 A MX 2021013663A MX 2021013663 A MX2021013663 A MX 2021013663A MX 2021013663 A MX2021013663 A MX 2021013663A MX 2021013663 A MX2021013663 A MX 2021013663A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- compositions
- related lung
- lung conditions
- treating biofilm
- Prior art date
Links
- 210000004072 lung Anatomy 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000003115 biocidal effect Effects 0.000 abstract 2
- 241000758250 Aspergillus fumigatus A1163 Species 0.000 abstract 1
- 241000590002 Helicobacter pylori Species 0.000 abstract 1
- 206010041925 Staphylococcal infections Diseases 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 230000032770 biofilm formation Effects 0.000 abstract 1
- 239000006227 byproduct Substances 0.000 abstract 1
- 229940037467 helicobacter pylori Drugs 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 abstract 1
- 244000005700 microbiome Species 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 210000002345 respiratory system Anatomy 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962846084P | 2019-05-10 | 2019-05-10 | |
| PCT/US2020/032039 WO2020231786A1 (en) | 2019-05-10 | 2020-05-08 | Compositions and methods for treating biofilm-related lung conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021013663A true MX2021013663A (es) | 2022-01-24 |
Family
ID=73046991
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021013663A MX2021013663A (es) | 2019-05-10 | 2020-05-08 | Composiciones y métodos para el tratamiento de las condiciones pulmonares relacionadas con biopeliculas. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11890341B2 (https=) |
| EP (1) | EP3958869A4 (https=) |
| JP (1) | JP2022531929A (https=) |
| KR (1) | KR20210154872A (https=) |
| CN (1) | CN114080236A (https=) |
| AU (1) | AU2020276206A1 (https=) |
| BR (1) | BR112021022632A2 (https=) |
| CA (1) | CA3138922A1 (https=) |
| CR (1) | CR20210618A (https=) |
| IL (1) | IL287961A (https=) |
| MX (1) | MX2021013663A (https=) |
| SG (1) | SG11202112387UA (https=) |
| WO (1) | WO2020231786A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5548121B2 (ja) | 2007-05-14 | 2014-07-16 | リサーチ ファウンデーション オブ ステイト ユニバーシティ オブ ニューヨーク | バイオフィルム中の細菌細胞における生理学的分散応答の誘導 |
| CN113873883A (zh) * | 2019-03-15 | 2021-12-31 | 轨迹Ip有限责任公司 | 用于生物膜的强化治疗和预防的材料和方法 |
| US20210069276A1 (en) * | 2019-09-09 | 2021-03-11 | LiquidPro Ltd. | Ear spray device and ear protection composition for preventing water related ear canal disorders |
| US12334224B2 (en) * | 2020-04-14 | 2025-06-17 | Siemens Healthineers Ag | Cardiovascular assessment of patients suspected of having COVID-19 |
| US20230070870A1 (en) * | 2021-09-09 | 2023-03-09 | Robert V. West, III | Covid Nasal Spray |
| BR102022016098A2 (pt) * | 2022-08-12 | 2024-02-20 | Universidade Estadual De Campinas | Formulação antiviral e intranasal |
| CN115400105B (zh) * | 2022-10-12 | 2023-08-22 | 湖北省农业科学院畜牧兽医研究所 | 焦棓酸在制备抗马链球菌兽疫亚种药物中的应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63182029A (ja) | 1987-01-22 | 1988-07-27 | Agency Of Ind Science & Technol | リポソ−ム |
| EP0540074A1 (en) | 1991-10-09 | 1993-05-05 | ENIRICERCHE S.p.A. | Cloning and sequencing of that chromosomal DNA region of bacillus subtilis comprising the SRFA operon which encodes the multienzymatic complex surfactin synthetase |
| JP2003246717A (ja) | 2002-02-22 | 2003-09-02 | Lion Corp | 口腔用組成物 |
| MXPA05013340A (es) | 2003-06-09 | 2006-03-09 | Nastech Pharm Co | Composiciones y metodos para liberacion mucosal incrementada de la hormona del crecimiento. |
| WO2009090656A2 (en) | 2008-01-18 | 2009-07-23 | Hadasit Medical Research Services & Development Ltd. | Combination therapy of beta-glycolipids and antibodies for the treatment of immune-related disorders |
| US9603876B2 (en) | 2008-09-25 | 2017-03-28 | New York University | Compositions and methods for restoring gastrointestinal microbiota following antibiotic treatment |
| CA2760248C (en) | 2009-04-30 | 2019-05-28 | Actogenix Nv | Cryoprotectants for freeze drying of lactic acid bacteria |
| EA037276B1 (ru) * | 2010-04-27 | 2021-03-03 | Лисандо Аг | Способы устранения или уменьшения бактериальной биопленки |
| MX2014009103A (es) | 2012-01-27 | 2015-11-18 | Gfs Corp Aus Pty Ltd | Métodos para producir biosurfactantes. |
| JP2014034552A (ja) * | 2012-08-09 | 2014-02-24 | Kao Corp | バイオフィルム形成抑制剤 |
| CN103007287A (zh) | 2012-09-29 | 2013-04-03 | 湖州紫金生物科技有限公司 | 一种鼠李糖脂作为药物口服促吸收剂的应用 |
| US9585903B2 (en) * | 2013-09-30 | 2017-03-07 | Council Of Scientific & Industrial Research | Pharmaceutical composition comprising sophorolipid in combination with an antibiotic |
| US20170014437A1 (en) * | 2014-04-03 | 2017-01-19 | Syracuse University | Synthetic disugar hydrocarbons as natural analogs to control microbial behaviors |
| CA2943049A1 (en) * | 2014-04-08 | 2015-10-15 | Aradigm Corporation | Liposomal ciprofloxacin formulations with activity against non-tuberculous mycobacteria |
| WO2015156904A1 (en) * | 2014-04-08 | 2015-10-15 | Aradigm Corporation | Liposomes that form drug nanocrystals after freeze-thaw |
| US20170304411A1 (en) * | 2014-10-24 | 2017-10-26 | Hprd - Health Products Research And Development Lda | Topical formulation for treating skin or mucosal infections, preparation method and uses thereof |
| WO2018049182A2 (en) * | 2016-09-08 | 2018-03-15 | Locus Solutions, Llc | Distributed systems for the efficient production and use of microbe-based compositions |
-
2020
- 2020-05-08 AU AU2020276206A patent/AU2020276206A1/en not_active Abandoned
- 2020-05-08 CR CR20210618A patent/CR20210618A/es unknown
- 2020-05-08 CN CN202080050217.7A patent/CN114080236A/zh active Pending
- 2020-05-08 BR BR112021022632A patent/BR112021022632A2/pt not_active IP Right Cessation
- 2020-05-08 SG SG11202112387UA patent/SG11202112387UA/en unknown
- 2020-05-08 KR KR1020217040555A patent/KR20210154872A/ko not_active Withdrawn
- 2020-05-08 WO PCT/US2020/032039 patent/WO2020231786A1/en not_active Ceased
- 2020-05-08 JP JP2021566455A patent/JP2022531929A/ja active Pending
- 2020-05-08 MX MX2021013663A patent/MX2021013663A/es unknown
- 2020-05-08 EP EP20806673.8A patent/EP3958869A4/en not_active Withdrawn
- 2020-05-08 CA CA3138922A patent/CA3138922A1/en active Pending
- 2020-05-11 US US16/871,504 patent/US11890341B2/en active Active
-
2021
- 2021-11-09 IL IL287961A patent/IL287961A/en unknown
-
2024
- 2024-02-06 US US18/434,064 patent/US20240181065A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US11890341B2 (en) | 2024-02-06 |
| CA3138922A1 (en) | 2020-11-19 |
| AU2020276206A1 (en) | 2021-12-02 |
| SG11202112387UA (en) | 2021-12-30 |
| US20200353085A1 (en) | 2020-11-12 |
| EP3958869A4 (en) | 2022-11-16 |
| CN114080236A (zh) | 2022-02-22 |
| BR112021022632A2 (pt) | 2022-01-04 |
| WO2020231786A1 (en) | 2020-11-19 |
| KR20210154872A (ko) | 2021-12-21 |
| CR20210618A (es) | 2022-03-11 |
| IL287961A (en) | 2022-01-01 |
| JP2022531929A (ja) | 2022-07-12 |
| EP3958869A1 (en) | 2022-03-02 |
| US20240181065A1 (en) | 2024-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021013663A (es) | Composiciones y métodos para el tratamiento de las condiciones pulmonares relacionadas con biopeliculas. | |
| WO2020149756A3 (en) | Chitosan-based nanocomposite as an antimicrobial agent and corrosion inhibitor | |
| WO2007130655A3 (en) | Phage derived antimicrobial activities | |
| WO2009126502A3 (en) | Methods of inhibiting and treating biofilms using glycopeptide antibiotics | |
| WO2009009171A3 (en) | Methods for preventing or treating infectious diseases using gallium compounds | |
| MX2021011147A (es) | Materiales y metodos para mejorar el tratamiento y prevencion de las biopeliculas. | |
| WO2009091856A3 (en) | Beta-lactamase inhibitors | |
| WO2018152436A8 (en) | Phenazine derivatives as antimicrobial agents | |
| WO2018208985A3 (en) | Antibacterial compounds | |
| WO2013102021A3 (en) | LOW pH DISINFECTANT COMPOSITION | |
| WO2009124871A3 (en) | Composition having biocide activity for aqueous preparations | |
| MX2017006383A (es) | Terapia de combinacion para el tratamiento de infecciones bacterianas resistentes. | |
| MX2017012545A (es) | Compuestos heterociclicos y su uso en la prevencion o tratamiento de las infecciones bacterianas. | |
| PH12017501019A1 (en) | Isoxazole hydromaxamic acid compounds as lpxc inhibitors | |
| WO2009077844A3 (en) | Inhibitors of biofilm formation of gram-positive and gram-negative bacteria | |
| PH12013500527A1 (en) | Oral composition | |
| WO2021089768A3 (en) | Treatment and prevention of a neurodegenerative disorder | |
| MX2021001564A (es) | Diazabiciclooctanonas como inhibidores de serina beta-lactamasas. | |
| MX2021005966A (es) | Nuevo derivado de imidazol. | |
| NZ610396A (en) | Use of chelating agent and peptide antimicrobial compounds | |
| MX2020000576A (es) | Compuestos quimicos. | |
| PH12020550222A1 (en) | Gluconic acid derivatives for use in the treatment and/or prevention of microbial infections | |
| WO2010123599A3 (en) | Anti-bacterial compositions and methods including targeting virulence factors of staphylococcus aureus | |
| WO2017011730A3 (en) | Phenazine derivatives as antimicrobial agents | |
| WO2009099405A3 (en) | Antibacterial compositions and methods of treatment |